Evidence map›Paper›PMID 18751681›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2009

Ruthenium red protects HepG2 cells overexpressing CYP2E1 against acetaminophen cytotoxicity.

Adam Holownia, Jakub Jablonski, Anna Skiepko, Robert Mroz, Edyta Sitko, Jan J Braszko

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Adam HolowniaDepartment of Clinical Pharmacology, Medical Academy at Bialystok, Waszyngtona 15A, 15-274, Bialystok, Poland. Holow_Sinai@hotmail.com
Jakub Jablonski
Anna Skiepko
Robert Mroz
Edyta Sitko
Jan J Braszko
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the mechanisms of acetaminophen (APAP) cytotoxicity in HepG2 cells overexpressing cytochrome p4502E1, particularly the role of oxidative/nitrosative stress and ryanodine Ca2+ channel. Cells were grown for 24 h with APAP in the presence or absence of 4-methylpyrazole (4MP), L-arginine methyl ester (L-NAME), superoxide dismutase (SOD), or ruthenium red (RuR). Drug cytotoxicity was also tested in cells pretreated overnight with V-PYRRO/NO. APAP was without effect on empty vector-transfected cells, but damaged CYP2E1-transfected cells and this was abolished by RuR, reduced by 4MP, or V-PYRRO/NO but affected by L-NAME or SOD. APAP increased microsomal [3H]-ryanodine binding, while microsomal Ca2+ uptake was significantly lowered. RuR increased net microsomal Ca2+ uptake and normalized cytosolic Ca2+ levels. We can conclude that neither oxidative nor nitrosative stress is relevant to APAP cytotoxicity in cultured HepG2 cells, but our results point to ryanodine receptors as a potential crucial protein in the early stages of APAP cytotoxicity.

Indexed as

AcetaminophenAnalgesics, Non-NarcoticAntioxidantsCalciumCell SurvivalColoring AgentsCytochrome P-450 CYP2E1FomepizoleHumansMicrosomes, LiverNG-Nitroarginine Methyl EsterNitric OxideNitric Oxide DonorsOxidation-ReductionOxidative StressPyrazolesAcetaminophenAnalgesics, Non-NarcoticAntioxidantsCalciumColoring AgentsCytochrome P-450 CYP2E1FomepizoleNG-Nitroarginine Methyl EsterNitric OxideNitric Oxide DonorsO(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolatePyrazolesPyrrolidinesRuthenium RedRyanodine Receptor Calcium Release ChannelSuperoxide Dismutase

Identifiers

PMID18751681
OpenAlexW2005099828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.